Show simple item record

dc.contributor.authorBedard, Philippe L
dc.contributor.authorFreedman, Orit C
dc.contributor.authorHowell, Anthony
dc.contributor.authorClemons, Mark
dc.date.accessioned2009-04-02T16:14:35Z
dc.date.available2009-04-02T16:14:35Z
dc.date.issued2008-04
dc.identifier.citationOvercoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? 2008, 108 (3):307-17 Breast Cancer Res. Treat.en
dc.identifier.issn0167-6806
dc.identifier.pmid18351454
dc.identifier.doi10.1007/s10549-007-9606-8
dc.identifier.urihttp://hdl.handle.net/10541/59273
dc.description.abstractEndocrine therapy is probably the most important systemic therapy for hormone receptor positive breast cancer. Hormonal manipulation was the first targeted treatment employed in breast cancer therapy even before the role of the estrogen (ER) and progesterone receptors (PR) had been elucidated. Unfortunately, a substantial proportion of patients, despite being ER and/or PR positive, are either primarily resistant to hormone therapies or will develop hormone resistance during the course of their disease. Signaling through complex growth factor receptor pathways, which activate the ER are emerging as important causes of endocrine resistance. Targeted therapies, such as signal transduction inhibitors (STIs), are being explored as agents to be able to potentially overcome this crosstalk and thus, resistance to hormone treatment. This article reviews the biology of the ER, the proposed mechanisms of endocrine resistance, and ongoing clinical trials with STIs in combination with hormonal manipulation as a means to overcome endocrine resistance.
dc.language.isoenen
dc.subjectEndocrine Resistanceen
dc.subjectEstrogen Receptoren
dc.subjectBreast Canceren
dc.subjectEndocrine Therapyen
dc.subjectHormone-Dependent Canceren
dc.subject.meshAnimals
dc.subject.meshAntineoplastic Agents, Hormonal
dc.subject.meshBreast Neoplasms
dc.subject.meshClinical Trials as Topic
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshNeoplasms, Hormone-Dependent
dc.subject.meshReceptors, Estrogen
dc.subject.meshSignal Transduction
dc.titleOvercoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?en
dc.typeArticleen
dc.contributor.departmentDivision of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada.en
dc.identifier.journalBreast Cancer Research and Treatmenten
html.description.abstractEndocrine therapy is probably the most important systemic therapy for hormone receptor positive breast cancer. Hormonal manipulation was the first targeted treatment employed in breast cancer therapy even before the role of the estrogen (ER) and progesterone receptors (PR) had been elucidated. Unfortunately, a substantial proportion of patients, despite being ER and/or PR positive, are either primarily resistant to hormone therapies or will develop hormone resistance during the course of their disease. Signaling through complex growth factor receptor pathways, which activate the ER are emerging as important causes of endocrine resistance. Targeted therapies, such as signal transduction inhibitors (STIs), are being explored as agents to be able to potentially overcome this crosstalk and thus, resistance to hormone treatment. This article reviews the biology of the ER, the proposed mechanisms of endocrine resistance, and ongoing clinical trials with STIs in combination with hormonal manipulation as a means to overcome endocrine resistance.


This item appears in the following Collection(s)

Show simple item record